Regulation of CRABP-II expression by MycN in Wilms tumor

Experimental Cell Research

Volumn 314, Issue 20, 2008, Pages 3663-3668

  Gupta, Anu ^a   Kessler, Patricia ^a   Rawwas, Jawhar ^b   Williams, Bryan R G ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

CRABP II; DNA methylation; MycN; Wilms tumor

Indexed keywords

BINDING PROTEIN; PROTEIN CRABP II; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; DEMETHYLATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR MECHANICS; NEPHROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 56249108694     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.09.029     Document Type: Article

References (30)

1. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16 (2000) 168-174
2. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomaki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., and Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24 (2000) 132-138
3. Feinberg A.P., and Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 4 (2004) 143-153
4. Feinberg A.P., and Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 (1983) 89-92
5. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., and Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
6. Cho M., Uemura H., Kim S.C., Kawada Y., Yoshida K., Hirao Y., Konishi N., Saga S., and Yoshikawa K. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br. J. Cancer 85 (2001) 563-567
7. Nakayama M., Wada M., Harada T., Nagayama J., Kusaba H., Ohshima K., Kozuru M., Komatsu H., Ueda R., and Kuwano M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92 (1998) 4296-4307
8. Hanada M., Delia D., Aiello A., Stadtmauer E., and Reed J.C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82 (1993) 1820-1828
9. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., and Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 7149-7153
10. Gupta A., Godwin A.K., Vanderveer L., Lu A., and Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 63 (2003) 664-673
11. Fang J.Y., Zhu S.S., Xiao S.D., Jiang S.J., Shi Y., Chen X.Y., Zhou X.M., and Qian L.F. Studies on the hypomethylation of c-myc, c-Ha-ras oncogenes and histopathological changes in human gastric carcinoma. J. Gastroenterol. Hepatol. 11 (1996) 1079-1082
12. Nishigaki M., Aoyagi K., Danjoh I., Fukaya M., Yanagihara K., Sakamoto H., Yoshida T., and Sasaki H. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 65 (2005) 2115-2124
13. Strichman-Almashanu L.Z., Lee R.S., Onyango P.O., Perlman E., Flam F., Frieman M.B., and Feinberg A.P. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res. 12 (2002) 543-554
14. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem. J. 348 Pt 3 (2000) 481-495
15. Bastie J.N., Despouy G., Balitrand N., Rochette-Egly C., Chomienne C., and Delva L. The novel co-activator CRABPII binds to RARalpha and RXRalpha via two nuclear receptor interacting domains and does not require the AF-2 'core'. FEBS Lett. 507 (2001) 67-73
16. Tavakkol A., Griffiths C.E., Keane K.M., Palmer R.D., and Voorhees J.J. Cellular localization of mRNA for cellular retinoic acid-binding protein II and nuclear retinoic acid receptor-gamma 1 in retinoic acid-treated human skin. J. Invest. Dermatol. 99 (1992) 146-150
17. Korkola J.E., DeVries S., Fridlyand J., Hwang E.S., Estep A.L., Chen Y.Y., Chew K.L., Dairkee S.H., Jensen R.M., and Waldman F.M. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 63 (2003) 7167-7175
18. Bertucci F., Houlgatte R., Benziane A., Granjeaud S., Adelaide J., Tagett R., Loriod B., Jacquemier J., Viens P., Jordan B., Birnbaum D., and Nguyen C. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum. Mol. Genet. 9 (2000) 2981-2991
19. Li C.M., Guo M., Borczuk A., Powell C.A., Wei M., Thaker H.M., Friedman R., Klein U., and Tycko B. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am. J. Pathol. 160 (2002) 2181-2190
20. Li W., Kessler P., and Williams B.R. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 24 (2005) 457-468
21. Hibbs K., Skubitz K.M., Pambuccian S.E., Casey R.C., Burleson K.M., Oegema Jr. T.R., Thiele J.J., Grindle S.M., Bliss R.L., and Skubitz A.P. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165 (2004) 397-414
22. Tsibris J.C., Segars J., Coppola D., Mane S., Wilbanks G.D., O'Brien W.F., and Spellacy W.N. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil. Steril. 78 (2002) 114-121
23. Vo H.P., and Crowe D.L. Transcriptional regulation of retinoic acid responsive genes by cellular retinoic acid binding protein-II modulates RA mediated tumor cell proliferation and invasion. Anticancer Res. 18 (1998) 217-224
24. Hathout Y., Riordan K., Gehrmann M., and Fenselau C. Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. J. Proteome Res. 1 (2002) 435-442
25. Samuel S., and Bernstein L.R. Adhesion, migration, transcriptional, interferon-inducible, and other signaling molecules newly implicated in cancer susceptibility and resistance of JB6 cells by cDNA microarray analyses. Mol. Carcinog. 39 (2004) 34-60
26. Gupta A., Williams B.R., Hanash S.M., and Rawwas J. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in Neuroblastoma. Cancer Res. 66 (2006) 8100-8108
27. Li X.H., and Ong D.E. Cellular retinoic acid-binding protein II gene expression is directly induced by estrogen, but not retinoic acid, in rat uterus. J. Biol. Chem. 278 (2003) 35819-35825
28. Loughney A.D., Kumarendran M.K., Thomas E.J., and Redfern C.P. Variation in the expression of cellular retinoid binding proteins in human endometrium throughout the menstrual cycle. Hum. Reprod. 10 (1995) 1297-1304
29. Robertson K.D., and Wolffe A.P. DNA methylation in health and disease. Nat. Rev. Genet. 1 (2000) 11-19
30. Sharrard R.M., Royds J.A., Rogers S., and Shorthouse A.J. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br. J. Cancer 65 (1992) 667-672